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The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are recessively inherited neurodegenerative disorders that affect humans and other
animals, characterised by brain atrophy and the accumulation of lysosome derived fluorescent storage bodies in neurons and most other cells.
Common clinical signs include blindness, ataxia, dementia, seizures and premature death. The associated genes for six different human forms have
been identified (CLN1, CLN2, CLN3, CLN5, CLN6 and CLN8), and three other human forms suggested (CLNs 4, 7 and 9). A form of NCL in
Australian Devon cattle is caused by a single base duplication (c.662dupG) in bovine CLN5. This mutation causes a frame-shift and premature
termination (p.Arg221GlyfsX6) which is predicted to result in a severely truncated protein, analogous to disease causing mutations in human
Finnish late infantile variant NCL (CLN5), and a simple genetic diagnostic test has been developed. The symptoms and disease course in cattle
also matches CLN5. Only one initiation site was found in the bovine gene, equivalent to the third of four possible initiation sites in the human
gene. As cattle are anatomically and physiologically similar to humans with a human-like central nervous system and easy to maintain and breed,
they provide a valuable alternative model for CLN5 studies.
© 2006 Elsevier B.V. All rights reserved.Keywords: NCL; Batten disease; CLN5; Cattle; Lysosomal storage disease; Animal model1. Introduction
The neuronal ceroid lipofuscinoses (NCLs, Batten disease)
are a group of inherited neurodegenerative lysosomal storage
diseases of humans [1,2] and other animals including Australian
Devon cattle [3–5]. Collectively they are the most commonly
inherited progressive neurodegenerative disease in children,
occurring at an estimated frequency of one per 12,500 live
births in the United States [6]. Common clinical features include
progressive ataxia, blindness, mental retardation and seizures
leading to premature death [2,7].
Traditionally, human NCLs were classified into four forms
(infantile, late infantile, juvenile and adult NCL) according to⁎ Corresponding author. Tel.: +61 2 9351 1604; fax: +61 2 9351 1693.
E-mail address: itammen@camden.usyd.edu.au (I. Tammen).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.07.008age of onset, clinical phenotype and the ultrastructural and
histological properties of the accumulated storage material.
Recent molecular genetic studies have identified disease
causing mutations in six different underlying genes, each
associated with a different form; CLN1 (infantile NCL), CLN2
(classical late infantile NCL), CLN3 (Juvenile NCL), CLN5
(Finnish variant late infantile NCL), CLN6 (variant late infantile
NCL), and CLN8 (Northern progressive epilepsy) [2]. A total of
167 causative mutations and 35 polymorphisms have been
identified in these six genes (http://www.ucl.ac.uk/ncl/, 2006).
Other disease forms proposed but for which no genes have yet
been identified include a CLN7 Turkish variant NCL [8], CLN4
adult onset cases [9] and a recently suggested CLN9 variant
[10].
The pathological hallmarks associated with the NCLs
include profound brain and retinal atrophy and the accumulation
of proteins in fluorescent lysosomal storage bodies within
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including the form in Devon cattle, the abnormally stored
protein is subunit c of mitochondrial ATP synthase [5,11,12].
The protein stored is the complete and normal mitochondrial
protein, including the trimethylation of lysine 43, and is not
modified or processed in any disease specific way [13].
Despite recent genetic advances there is still a very limited
understanding of the pathobiology of these diseases. No
effective treatments have been developed but human clinical
trials for gene therapy and neuronal stem cell therapies have
recently been approved for CLN1 and CLN2 [14]. Progress
largely depends on genetically defined animal models for
analysis of biochemical and pathological changes and as
vehicles for testing therapies. Animal models can provide a
large cohort of individuals with genetically identical disease.
Large domestic animal models, including cattle, are particularly
valuable. Clinical signs and pathology in a naturally occurring
form diagnosed in a herd of Devon cattle closely resemble those
seen in human CLN5, particularly severe cortical atrophy,
profound neuronal loss and retinal degeneration [2–5]. Cattle
have a large gyrencephalic human-like brain important for the
development of effective treatments, whereas mice have small
lissencephalic brains.
We have located the disease-causing gene and identified the
mutation responsible for NCL in affected Devon cattle as a
single base duplication in bovine CLN5, which results in a
frame-shift leading to premature termination. A herd can now
be maintained for further research and characterisation of this
disorder.2. Materials and methods
2.1. Animals and bacterial artificial chromosomes (BACs)
Cattle were raised and maintained outdoors under normal Australian
pastoral conditions. Animal health was monitored in accordance with the
University of Sydney, Australia animal ethics requirements and all interven-
tions were covered under these guidelines. Blood, hair and tissue samples
were collected from 15 affected animals that presented with clinical signs, 34
known carriers that produced affected offspring and 395 cattle that showed no
clinical signs at the time of sample collection. Twelve of the 15 affected
animals used in this study were described in the original reports [3,4], which
included a detailed phenotypic characterisation. DNA samples collected from
38 unrelated cattle of 10 different breeds (Angus, Hereford, Polled Shorthorn,
Charolais, Limousine, Simmental, Brahman, Santa Gertrudis, Holstein-
Friesian and Jersey) were used as controls for mutation analysis. Six BAC
clones were obtained from André Eggen (INRA, France) after PCR screening
with bovine CLN5 specific primers and BAC clone 832B03 was used for
sequencing.
2.2. Nucleic acid extractions
DNAwas extracted from blood and tissue samples using a QIAamp mini kit
(Qiagen, Valencia, CA, USA). Hair roots, 3 per sample, were boiled for 15 min in
50μl of 200mMNaOH, and after brief centrifugation the solutionwas neutralized
with 50 μl of 200 mM HCl, 100 mM Tris–Cl, pH 8.5, to extract genomic DNA.
BAC DNAwas extracted using a QIAamp midi preparation kit (Qiagen).
Total RNAwas extracted from fibroblasts cultured from 3 affected animals
and an unrelated control [15], and brain, liver, heart and skeletal muscle from an
affected and two normal animals using TRI REAGENT (Sigma, St. Louis, MO,
USA). Complementary DNA (cDNA) was generated from 2–4 μg of total RNAusing Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) and
oligo d(T)15 for the primer.
2.3. Primers
Bovine and human gene specific oligonucleotide primers (Table 1) were
designed from bovine ESTs (CB455600, CB077350, BI3004716, CB171352,
BM480980) and human genomic (NM_006493) and mRNA (NT_086804)
CLN5 sequences obtained from Genbank. Subsequent bovine gene specific
primers were based on sequence determined during this investigation and the
published BTA12 contiguous sequence (AAFC02058816), which contains
bovine CLN5.
2.4. Polymerase chain reaction (PCR)
PCR reactions contained 1x Qbuffer (Qiagen), 200 μM dNTP, 3 pmol of
each primer, 1U Hotstart Taq DNA polymerase (Qiagen) and 1.5 mMMgCl2 in
a total volume of 20 μl covered by a drop of mineral oil. The standard
amplification protocol consisted of 95 °C for 15 min followed by 40 cycles of
95 °C for 30 s, specific amplification temperature (Ta) for 30 s and 72 °C for
1 min. PCR conditions were optimized as required.
2.5. Detection of mRNA splicing
PCRs were performed on cDNA from affected and normal brain, liver and
heart muscle using primers in non-adjacent exons to identify potential splicing
variants. Forward primers in exons 1 and 2 and reverse primers in exons 3 and 4
were tested. The combination bCLN5_E2F1 and bCLN5_E4sp.2 (Table 1)
produced two different products when separated on a 1.5% agarose gel and both
products were sequenced after gel extraction using QIAquick gel extraction kit
(Qiagen).
2.6. Sequencing
PCR products were sequenced using a Sequitherm EXCEL II sequencing kit
(Epicenter Biotechnologies, Madison, WI, USA) and a LI-COR 4200 sequencer
(Lincoln, NE, USA). M13 tailed primers [16] (Table 1) were used to generate
the PCR products and simultaneous bi-directional sequencing was carried out
[17]. Alternatively, PCR product and direct BAC sequencing was performed
using a BigDye terminator v3.1 cycle sequencing kit (Applied Biosystems) on
an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). PCR products
were purified using EXOSAP-IT (Amersham Pharmacia Biotech, Piscataway,
NJ, USA) or Perfectprep Gel cleanup (Eppendorf, Hamburg, Germany).
Approximately 1.5 μg of purified BAC DNA was used for direct BAC
sequencing.
2.7. Sequence compilation and analysis
Sequence data generated during this study was aligned to 20661 bp of
bovine genomic sequence identified as bovine CLN5 through BLASTp [18]
searches and obtained from the bovine whole genome scan on NCBI
(AAFC02058816). Genescan sequence analysis [19] was performed with
ANGIS Biomanager (http://www.angis.org.au) to predict the coding sequence
for bovine CLN5 and Translate (GCG, Biomanager) to calculate the molecular
weight of the predicted amino acid sequence.
2.8. Direct DNA testing
A direct DNA test was developed to detect the disease associated single
base duplication identified in exon 4 of bovine CLN5. A PCR of a total volume
of 10 μl contained genomic DNA, 1X Qbuffer, 1.5 mM MgCl2 (Qiagen),
200 nM dNTP, 0.2 pmol infrared-labeled M13-29 primer (5′-CACGACGTTG-
TAAAACGAC-3′), 3 pmol of primers CLN5_E4sp.1 and CLN5_E4sp.2 (Table
1) each and 1U of Hotstar Taq polymerase (Qiagen). The standard amplification
Table 1
CLN5 primer sequence information
Primer name Primer sequence (5′–3′) Location (bp) c
bCLN5_5′UTR_F3 CGACACCCTGCGCTTAGT 5′UTR
bCLN5_I1R2 GCCAGGACGCAACTTCCTAC Intron 1
bCLN5_I1F2 TAAGATCTGGATTCTAAGATC Intron 1
bCLN5_I2R4 TGAACTGAAGAGGAACACCAA Intron 2
bCLN5_I2F3 ATGAGGGCAGGGAGTTAGAG Intron 2
bCLN5_I3R4 TTGAAACTTACCTGATATGG Intron 3
bCLN5_I3F3 TCAGAGGTATCTTGTGCCTT Intron 3
hCLN5_E2.1 a M13(-29)ATCCTTATTGTCAAGCTA Exon 2 (197–214)
hCLN5_E2.2 b M13(-38)AAGTGTCCCAGGAGGTC Exon 2 (319–335)
bCLN5_I2R2b M13(-38)TAGGCCCTAGACATGAAGTGAT Intron 2
bCLN5_I2F1a M13(-29)CTGCCTTCAGTCTTTCCCAGC Intron 2
bCLN5_E3.1a M13(-29)ATGCATGATGCCATTGGATT Exon 3 (343–362)
bCLN5_E3.2b M13(-38)CTAGAACTAACGTCCCATTTTCCT Exon 3 (524–547)
bCLN5_I3R2b M13(-38)TATAAATGCTGAAGCCCTCGTT Intron 3
bCLN5_I3F1a M13(-29)CACTCATTCCTTTTCTACAACTT Intron 3
bCLN5_E4sp.1a M13(-29)GGACTGTCCAAGCCAGCC Exon 4 (632–649)
bCLN5_E4sp.2 GGAACAGTCGTAGGATTCAAAAC Exon 4 (672–693)
bCLN5_E4.1a M13(-29)GCATGTTTAACAGAATGGCAA Exon 4 (566–586)
bCLN5_E4.2b M13(-38)ACTGATGTGCTGGTAGAAAGAA 3′ UTR
bCLN5_3′UTRR2b M13(-38)TAACATTGAGTCAAAAGATCCT 3′ UTR
bCLN5_3′UTR_R4 TCCTGAGGTACCATTACGCA 3′UTR
a M13(-29)= tailed primer: a CACGACGTTGTAAAACGAC extension is included at the 5′ end of the primer.
b M13(-38) tailed primer: a TTTCCCAGTCACGACGTTG extension is included at the 5′ end of the primer [16].
c Primer position based on Genbank submission DQ421787.
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30 s, 56 °C for 30 s and 72 °C for 1 min. PCR products were analyzed on 8%
polyacrylamide gels using a LI-COR 4200 sequencer. Homozygous wild-type
(normal) individuals yield a single 62 bp product, homozygous affected
individuals a single 63 bp product and heterozygous individuals both the 62 and
63 bp products (Fig. 3).Table 2
Comparison of bovine and human CLN5
Exon/intron
identification
Exon size (bp) Intron size (bp) % Exon
conservation
Bovine Human Bovine Human
1 170 320 3673 2791 74
2 166 166 991 673 89
3 226 226 >2000 4330 91
4 515 512 93
The bovine exon/intron structure was predicted with Genescan from a bovine
genomic contig (AAFC02058816) and confirmed by genomic and cDNA
sequencing (DQ421787). The bovine cDNA sequence was compared with
human CLN5mRNA sequence (NM_006493) and exonic conservation between
the two species was calculated using BESTFIT (GCG).3. Results
CLN5 was selected as a candidate gene for this disease in
cattle on the basis of phenotypic similarities between affected
cattle and CLN5 affected humans as detailed in Discussion.
Genomic and mRNA sequences of normal and affected cattle
were compared to determine if bovine CLN5 contained the
disease causing mutation.
3.1. Characterisation of bovine CLN5
Bovine CLN5 genomic sequence was assembled from
6318 bp of BAC DNA containing the CLN5 insert, genomic
DNA and mRNA obtained from both affected and normal
Devon cattle and compared to the BTA12 contig (NCBI).
Genescan analysis and cDNA sequencing was used to predict
the coding sequence in bovine CLN5. This identified a coding
region of 1077 nucleotides (DQ421787) organized into 4 exons
with a similar gene structure and homology to the human gene
(Table 2). cDNA sequencing confirmed this structure. Exon 1 is
the least conserved and is substantially longer in humans than in
cattle (Table 2).
The amino acid sequence predicted is a polypeptide of 358-
amino acids (Fig. 1) with a predicted molecular weight of41.22 kDa. Fig. 1 shows the alignment of the predicted bovine
(DQ421787), human (NM_006493; NT_086804), murine
(XM_127882) and canine (NM_001011556) CLN5 proteins.
The similarities between the bovine CLN5 and the human,
mouse and dog homologous proteins are 88.5%, 83.6% and
92.3%, respectively. There is considerable interspecies varia-
tion in the initial sequence of the protein, which codes for
exon 1.
Only one (exons 2–4) out of the three primer combinations
tested to confirm exon/intron boundaries (exons 1–4, exons 1–3
and exons 2–4) consistently produced two PCR products (Fig.
4). Sequencing of both bands from normal and affected
individuals showed that the low molecular weight band does
not contain exon 3 (Fig. 4). This possible splicing variant was
shown to be present in both normal and affected cattle brain,
liver, heart and fibroblasts, thus it is not disease associated. The
other tested primer combinations consistently produced non-
Fig. 1. Alignment of human, mouse, dog and cattle CLN5 (N=normal and A=affected) polypeptides. Black or gray background indicates that the amino acids are
conserved in all or several species, respectively. Positions of known human (f=Fin minor (p.Trp75X); S=Swedish (p.Trp224LeufsX30); E=European (p.
Asp279Asn); F=Fin Major (p.Tyr392X); C=Columbian (p.Arg112His)), canine (D=dog (p.Gln207X)) and bovine (B=bovine (p.Arg221GlyfsX6)) mutations are
indicated above the sequence. The affected cattle sequence [Bovine_(A)] and resulting premature stop codon are highlighted by (*). Mutation nomenclature follows
the recommendations of the Human Genome Variation Society (http://www.genomic.unimelb.edu.au/mdi/mutnomen/index.html).
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conditions.
3.2. Mutation identification
A single base duplication in exon 4 of bovine CLN5
(c.662dupG) was first found in an affected Devon bull (Fig. 2).This duplication results in a frame-shift, predicted to introduce a
premature termination codon six amino acids downstream of the
duplication site resulting in the loss of 132 C-terminal amino
acids (Fig. 1), thus suggesting it as a strong candidate for the
disease specific mutation. Accordingly a further five affected,
nine clinically normal and six known carrier Devon cattle were
sequenced for confirmation of disease association. All affected
Fig. 2. Sequence chromatograph of an unrelated Angus cow (a) and an affected
Devon bull (b) showing the 1 bp duplication c.662dupG (*).
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animals were heterozygous and no normal individual carried the
duplication. No other allelic variants were found in the CLN5
coding sequences determined from both normal and affected
Devon cattle.
3.3. Disease association using a direct DNA test
In order to confirm the disease association of the duplication,
a direct DNA test was developed based on the 1 bp difference
between the two forms. Primers flanking the duplication were
used to generate PCR fragments from 455 Devon cattle and 38
unrelated cattle from 10 different breeds. The genotype of each
individual was determined from the size difference between
PCR products (Fig. 3). All 15 affected Devon cattle genotyped
were homozygous for the duplication, 43 heterozygous cattle
(of which 34 were confirmed as known carriers by breeding
records) yielded both the long and short products, and 397
control cattle only the shorter allele.
Two-point linkage analysis between the duplication and the
disease phenotype using CRI-MAP [20] gave a LOD score of
11.74 and a recombination fraction (θ) of 0.00. Hardy–
Weinberg equilibrium and Chi-square (χ2) analysis showed
that there was no significant difference (0.95) between the
observed and expected values between phenotypes and
genotypes. The 38 animals from different breeds were all
homozygous normal at the site of this mutation.Fig. 3. DNA test for the bovine CLN5 c.662dupG duplication. Gel electrophoresis o
affected allele: Normal animals (N) are homozygous for the 62 bp allele, carriers (C)
(0=blank).4. Discussion
The reasons for regarding c.662dupG in exon 4 of bovine
CLN5 (Fig. 2) in affected Devon cattle as the disease causing
mutation are compelling.
Firstly, CLN5 is a positional candidate gene. Bovine CLN5
has been mapped on a radiation hybrid panel to bovine
chromosome 12 [21] and the location was confirmed by Genbank
annotation. The original human linkage studies delineated this
variant (Finnish late infantile variant) from the classical late
infantile form (CLN2) and positioned it at the orthologous region
of the human genome, HSA 13q21–q23 [22,23].
Secondly, the duplication is tightly linked to the disease
status. There was no recombination between the mutation and
the disease phenotype, when tested over a large number of
normal, heterozygote and affected cattle (n=92, LOD=11.74,
θ=0.00). No phenotypically normal Devon cattle tested from
the same herd were homozygous for the duplication, despite the
rather high frequency of this allele in this population. No other
allelic variants were found within the coding sequence of
normal and affected Devon cattle. The duplication was not seen
in unrelated animals from different breeds.
Thirdly, the frame-shift introduced by c.662dupG is
predicted to completely disrupt the protein function by
introducing a premature stop codon causing a major truncation
of the coded protein to a polypeptide of only 225 amino acids
(Fig. 1).
Analogous human mutations cause NCL. Human CLN5 was
identified by positional cloning as a four exon gene spanning
13 kb and encoding a maximum 407 amino acids [24]. Three of
the five disease causing mutations reported (www.ucl.ac.uk/ncl;
2006) encode premature stop codons. FINmajor is a 2-bp
deletion in exon 4 (c.1175delAT) resulting in premature
termination (p.Tyr392X) and a longer putative product than
the bovine mutation (Fig. 1). Finminor is a single base sub-
stitution in exon 1 (c.225G>A) resulting in premature
termination (p.Trp75X) and a shorter product. A third mutation,
a single base duplication (c.669dupC) identified in one Swedish
and one Finnish patient results in a truncated putative product
(p.Trp224LeufsX30) [25] similar in length to the predicted
aberrant bovine protein. A nonsense mutation causing a
truncation has also been found in Border collie dogs (p.
Gln207X) [26] (Fig. 1).n an 8% polyacrylamide gel reveals the 1 bp difference between the normal and
show both alleles and the affected animal (A) is homozygous for the 63 bp allele
Fig. 4. Bovine exon 3 splicing variants. Lane 1: 100 bp ladder; lane 2: blank; lane 3: normal brain (734 and 960 bp) and lane 4: affected brain (734 and 960 bp) (1.5%
agarose gel). Partial sequence chromatographs of the gel extracted 734 and 960 bp bands from the affected Devon cattle brain show the spicing sites.
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recognized in human CLN5. A “European form” is caused by
a single base change, c.835G>A, resulting in p.Asp279Asn
[24], and a c.1627G>A substitution leading to p.Arg112His has
been described in three related Columbian patients [27].
Finally, pathological similarities between human CLN5 and
the bovine form of NCL are consistent with this mutation being
the cause of the disease in Devon cattle. Both the bovine disease
and human CLN5 variants accumulate subunit c within the
neurons and other cells of the body [5,28]. Visual impairment
followed by blindness accompanied by the destruction of rod
and cone photoreceptors within the eye are shared symptoms
between humans and cattle. Behavioural characteristics in
affected cattle include walking in circles and repetitive head
tilting motions indicating altered motor responses, which also
occur in human CLN5 patients. Cerebral and cerebella
degeneration recorded within Devon cattle mirrors that
described in human patients [1–4]. Neurological degradation
occurs within the cerebrocortical gray matter of affected cattle
and there is substantial atrophy of the cerebral cortex, thinning
of the gyri in the occipital area, atrophy of the cerebellum and
dilation of the lateral ventricles as well as atrophy of the
hippocampus [3,5]. Premature death of affected cattle occurs at
approximately 2 years of age [3], a similar reduction in life
expectancy to human patients affected with Finnish variant
NCL, who succumb to the disorder at 8–12 years of age [29].
Bovine CLN5 shows high similarity to the homologous gene
in human, mouse, and dogs with 88.95%, 82.09%, and 89.55%
homology, respectively. Exons 2, 3 and 4 align well but the
alignment of nucleotide and protein sequences (Fig. 1) reveals a
higher level of variation in the initial part of the gene (exon 1).
This exon has a high GC content and was difficult to sequence.
The cDNA of human CLN5 has been published as 4.1 kb inlength with four potential methionine (AUG) initiation sites at
base pairs 1, 30, 50 and 62 [30].
Initially an open reading frame of 1380 bp was suggested,
coding for a 407-amino acid polypeptide containing two
transmembrane domains through initiation of translation at the
most 5′ AUG [24]. Later studies based on sequence comparison
and protein alignment with mouse CLN5 concluded that the
most 3′ AUG in humans (AUG62) is the major initiation site for
a 38 kDa protein [30,31]. Expression studies using transfected
COS-1 cells showed that the fourth initiation site in humans can
act as a translation initiator [31]. However, this study did not
evaluate the second or third initiation sites. A more careful
alignment of human, canine [26], murine and bovine CLN5
(Fig. 1) suggests that the third human initiation site is that which
is evolutionary conserved. This is the only initiation site in
bovine CLN5 and CLN5 in mice [31,32], dogs [26], therefore
only one translation product is possible in these species.
Initiation from this site is predicted to yield a 358 amino acid
protein in cattle homologous to a 358 amino acid human protein
initiated from the third human CLN5 initiation site. Further-
more, later studies on CLN5 do not support the initial prediction
as a transmembrane protein [30,31]. Based on protein structure
prediction programs and cell biology studies they suggest that
the CLN5 product is likely to be a soluble lysosomally targeted
glycoprotein [25,30,31,33].
Our results indicate a splice variant exists within bovine
CLN5 with exon 3 lacking in some transcripts (Fig. 4).
However, both normal and affected Devon cattle contain this
splice variant to some degree (Fig. 4) and it is therefore not
considered to be associated with the symptoms of this disorder.
Other natural splicing variants may exist. The presence of
alternative splicing variants is a possible explanation for the
multiple bands identified on Northern blots of human CLN5
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codes for a predicted protein of 122 amino acids. A CLN5
knockout mouse model has mimicked this natural splicing
variant by completely eliminating exon 3 [32].
Accessible animal models are invaluable for studying a large
number of aspects of inherited diseases. The strong similarities
in symptomology, behaviour and neuropathology and the nature
of the mutation, a premature stop codon, mimicking the
mutations in the majority of human CLN5 cases, makes this
disease in cattle a particularly accurate model of human CLN5.
A similar mutation has been recognized in Border collie dogs
which also contains a mutation in exon 4 of CLN5 resulting in
premature termination [26]. Cattle and dogs both have a human-
like gyrencephalic brain and for a number of purposes these
animals may be superior models to mice where the neurode-
generation is significantly less, largely subcortical and hippo-
campal, and the motor abnormalities are much milder [31].
Cattle are domestic production animals making them
economic to breed, raise, manage and maintain, despite their
size. Advanced reproductive techniques (ARTs) are routine and
can be used to produce a stable population of affected
individuals for therapeutic trials and treatments. The simple
gel based method of mutation detection provides a screen for
affected and heterozygous animals in commercial and research
herds, allowing for control of the disease in the field and
immediate identification of homozygous affected individuals
for preclinical pathology studies and therapeutic treatments.
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